Skip to content

Patient Education and Rheumatoid Arthritis

Patient Education Program for Individuals With Rheumatoid Arthritis: A Randomized Controlled Trial

Status
Active, not recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07170371
Acronym
PE and RA
Enrollment
88
Registered
2025-09-12
Start date
2025-09-05
Completion date
2026-03-30
Last updated
2025-09-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid Arthritis

Keywords

patient education

Brief summary

The goal of this clinical trial is to learn if a culturally adapted patient education program can help people with rheumatoid arthritis (RA) manage their disease and improve their quality of life. The main questions it aims to answer are: * Does the program improve patients' knowledge, self-management skills, and confidence in dealing with RA? * Does it lead to better quality of life and treatment adherence compared to usual care? Participants will: * Join group sessions and individual activities focused on RA education, self-care, and stress management * Take part in the program for 6 months, with regular follow-up visits * Complete questionnaires about symptoms, daily activities, and quality of life

Interventions

OTHERpatient education

A culturally adapted patient education program designed for individuals with rheumatoid arthritis. The program was developed through a structured needs assessment and based on established health behavior theories. It includes five core modules delivered over six months: understanding rheumatoid arthritis, monitoring disease activity, treatment strategies, nutrition, and stress management. Sessions combine group workshops and individual support, with interactive materials and practical exercises. The program aims to strengthen patients' knowledge, self-management skills, and quality of life compared to usual care.

OTHERUsual Care

patients will receive usual care only

Sponsors

Hassan II University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Intervention model description

Participants will be randomized into two parallel groups. One group will receive a culturally adapted patient education program in addition to usual medical care, while the other group will receive usual care alone. The two groups will be followed for 6 months, with comparative evaluation of outcomes related to self-management and quality of life.

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Adults (≥18 years) diagnosed with rheumatoid arthritis according to ACR/EULAR 2010 classification criteria * Stable pharmacological treatment for at least 3 months prior to enrollment * Ability to participate in group sessions and complete questionnaires * Provided written informed consent

Exclusion criteria

* Diagnosis of other systemic autoimmune or inflammatory rheumatic diseases (e.g., lupus, psoriatic arthritis) * Severe comorbidities that may interfere with participation (e.g., advanced heart failure, uncontrolled psychiatric illness) * Cognitive impairment or language barrier preventing comprehension of the program * Participation in another structured patient education program within the last 6 months

Design outcomes

Primary

MeasureTime frameDescription
AIMS2 Quality of lifeBaseline to 6 months after randomizationChange in health-related quality of life among participants, measured using validated patient-reported questionnaires (AIMS2) to assess physical, emotional, and social domains. The focus is on improvement in self-reported well-being and daily functioning.

Secondary

MeasureTime frameDescription
DAS-28Baseline to 6 months after randomizationChange in disease activity, assessed by the Disease Activity Score 28 (DAS28), including tender/swollen joint counts, ESR/CRP levels, and patient global assessment
ASESBaseline to 6 months after randomizationChange in patient self-efficacy for managing rheumatoid arthritis, assessed with the Arthritis Self-Efficacy Scale (ASES), covering pain, function, and other disease-related aspects.
MARSBaseline to 6 months after randomizationChange in treatment adherence measured by the Medication Adherence Rating Scale (MARS), focusing on consistency of drug intake and attitudes toward treatment.
BDIBaseline to 6 months after randomizationChange in depressive symptoms measured by the Beck Depression Inventory (BDI), and in perceived stress using standardized self-report tools

Countries

Morocco

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026